Related Experiment Videos
Immunosuppression for pancreatic islet transplantation
T Berney1, L H Buhler, P Majno
1Division of Visceral and Transplantation Surgery, Department of Surgery, Geneva University Hospitals, Geneva, Switzerland. thierry.berney@hcuge.ch
Transplantation Proceedings
|March 26, 2004
Summary
Islet transplantation protocols must balance immunosuppression and toxicity. A sirolimus-based, steroid-free regimen improved insulin independence but has long-term drawbacks, prompting research into alternatives for better islet transplant outcomes.
Area of Science:
- Immunology
- Transplantation Biology
- Endocrinology
Background:
- Islet transplantation is a promising therapy for type 1 diabetes.
- Standard immunosuppressive regimens, including corticosteroids and calcineurin inhibitors like tacrolimus, pose risks of islet toxicity and diabetogenicity.
- Optimizing immunosuppression is crucial for long-term graft survival and patient outcomes.
Purpose of the Study:
- To review current immunosuppressive strategies in islet transplantation.
- To highlight the advancements and limitations of sirolimus-based, steroid-free regimens.
- To discuss emerging alternatives and future perspectives for achieving immune tolerance in islet transplantation.
Main Methods:
- Review of existing literature on immunosuppression in islet transplantation.
- Analysis of clinical outcomes associated with different immunosuppressive protocols.
- Exploration of novel immunosuppressive agents and tolerance-inducing strategies.
Main Results:
- The Edmonton protocol (sirolimus-based, steroid-free, low-tacrolimus) significantly increased 1-year insulin independence rates from 13% to 80%.
- Long-term insulin independence decreased to 50% at 3 years, potentially due to prolonged tacrolimus exposure and sirolimus side effects.
- Alternative agents like cyclosporine, mycophenolate mofetil, and FTY720 are being investigated to mitigate toxicity.
Conclusions:
- Sirolimus-based, steroid-free immunosuppression represents a major advance in islet transplantation but requires optimization for long-term efficacy.
- Addressing tacrolimus-related toxicity and sirolimus side effects is essential for sustained insulin independence.
- Future strategies focusing on lymphocyte depletion and costimulatory blockade hold promise for achieving "prope tolerance" and improving islet transplant success.